Project Grant R37CA299888
Award Date
5/5/25
Completion Date
4/30/30
Dollars Obligated
$423K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
This federal Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is provided to Trustees of Indiana University, doing business as Indiana University Indianapolis, to conduct research on targeting the gene KLF10 to prevent cancer-associated muscle loss. The $239,239 award, with a period of performance from September 18, 2023 to August 31, 2024, aims...
This $205,700 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research supports research aimed at addressing the problem of rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance, and to test a novel combination therapy approach of DNA repair inhibition and targeted therapy to prevent resistance...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $551,848 to the Dana-Farber Cancer Institute, Inc. (DFCI) to investigate the molecular mechanisms of developmental reprogramming in colorectal cancer (CRC). The key objectives are to identify regulators of fetal gene reactivation in CRC cells, determine if the transcription factor SOX9 directly controls fetal gene expression, and evaluate the...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has awarded a $383,570 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Trustees of Indiana University, doing business as Indiana University Indianapolis. The grant, titled "Delineating the Contribution of Muscle Wasting to Tumor Progression," aims to better understand the relationship between skeletal muscle wasting and tumor progression in cancer patients. The...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $156,210 to support the research project "Metastatic Bone Disease and IL-6 as Drivers of Cachexia in Kidney Cancer" at Indiana University Indianapolis. The primary objective is to define the contribution of metastatic bone disease to cachexia in kidney cancer and identify key...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of Nebraska Medical Center (UNMC) to assess strategies for targeting transcriptional co-activators in colorectal cancer. The $439,367 award will fund a 5-year research project focused on understanding how the transcriptional coactivator PGC-1B promotes the survival of colorectal cancer cells, particularly in tumors with K-RAS mutations. The project aims to identify...
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program), supports research to investigate the impact of cancer on the vascular and lymphatic systems of the intestine, and how this contributes to the development of cancer-induced cachexia. The $502,563 grant awarded to Northwestern University aims to determine if deficiencies in the lymphatic and vascular endothelium are a significant underlying cause of cancer-induced cachexia,...
The National Cancer Institute (NCI) awarded a $506,309 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis). The grant, awarded on May 7, 2025, will fund a research project to investigate the mechanism by which ovarian cancer cells interact with their microenvironment to promote metastasis. Specifically, the research aims to determine how microenvironmental signals activate...
This $640,583 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance the efficacy of immunotherapy against metastatic colorectal cancer (MCRC). The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their metabolic fitness and anti-tumor immunity within the immunosuppressive MCRC tumor microenvironment. The project, awarded to Cold Spring Harbor Laboratory, involves three synergistic research...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award to the Icahn School of Medicine at Mount Sinai in the amount of $560,297 will fund a 5-year research project to functionally characterize "oncofetal stem cells" in colorectal cancer (CRC). The project aims to: Generate reporters to track the dynamics of CRC stem cell populations, including oncofetal stem cells and LGR5+ cancer stem cells. The researchers will then use these reporters coupled to a...